Shares of Moderna (NASDAQ: MRNA) were sinking 9% lower this week as of Thursday’s market close, according to data provided by S&P Global Market Intelligence. The decline appears to be the result of investors taking profits after Moderna stock soared 25% last week.
What’s behind the big moves for Moderna? Avian flu. Reports of human cases of H5N1 avian flu (also known as bird flu) in Australia and the U.S. caused several vaccine stocks to jump last week.
The sell-off in Moderna’s shares was even worse early on Wednesday with the stock falling as much as 13.9%. However, Moderna rebounded somewhat after The Financial Times reported that the U.S. government is close to finalizing a deal to fund a late-stage clinical study of Moderna’s experimental messenger RNA (mRNA) bird flu vaccine.
How big of a deal could bird flu be for Moderna?
Moderna executives didn’t mention the experimental bird flu vaccine at all in the company’s first-quarter conference call earlier this month. Investors probably shouldn’t make too much of the hoopla either at this point.
The number of bird flu cases in humans so far is low. H5N1 has a high mortality rate but isn’t very contagious between people. There haven’t been any signs yet that the virus is mutating in ways that increase its transmissibility.
Is Moderna stock a buy on the dip?
Even if there isn’t a significant opportunity for Moderna with its experimental bird flu vaccine, I think the stock is a good pick to buy on the dip. The company has several other potential catalysts on the way, notably including the anticipated U.S. approval of its respiratory syncytial virus (RSV) vaccine.
Should you invest $1,000 in Moderna right now?
Before you buy stock in Moderna, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Moderna wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $703,539!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
See the 10 stocks »
*Stock Advisor returns as of May 28, 2024
Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy.